Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed
in new markets - Fresenius Medical Care
for further growth - Fresenius Kabi
for better health - Fresenius Helios
for greater efficiency - Fresenius Vamed
close

Seizing opportunities > in new markets

Asia is an important growth market for Fresenius Medical Care. Approximately 620,000 patients with chronic kidney failure are currently being treated in this region, and every year this number increases by about 10 to 11%. We will continue to take advantage of this growth potential. The significant demand for dialysis services offers substantial opportunities to expand our network of clinics in the Asian countries.

In 2008, Fresenius Medical Care achieved sales of US$ 606 million in the Asia-Pacific region. Our goal is to continue our strong organic growth and to increase sales to more than US$ 800 million in constant currency by 2010.

FRESENIUS MEDICAL CARE IN ASIA
  2008 2007 Change
Sales (in million US$) 606 541 12%
Employees (December 31) 3,558 3,095 15%
Dialysis patients (December 31) 9,158 7,789 18%
Dialysis treatments (million) 1.34 1.21 11%
Dialysis clinics (December 31) 125 105 19%
 

READ MORE ABOUT FRESENIUS MEDICAL CARE >>

close
in new markets - Fresenius Medical Care
close

Seizing opportunities > for further growth

With the acquisition of APP Pharmaceuticals, Fresenius Kabi has achieved a leading position in the global market for intravenously administered generic drugs. APP Pharmaceuticals has a strong drug registration portfolio pending and over 70 products under development, opening up new growth opportunities.

At the same time, we are seizing the opportunity of introducing selected Kabi products into the US, with initial focus on parenteral nutrition. We are also planning to launch selected APP IV drugs outside the US.

APP PHARMACEUTICALS IN FIGURES
  2008
Sales US$ 777 million
EBITDA, adjusted* US$ 317 million
EBITDA margin, adjusted* 40.8%
Employees (December 31, full-time equivalent) 1,487
Production facilities 3
Produkte >100
Number of products ~17%
 

READ MORE ABOUT FRESENIUS KABI >>

close
for further growth - Fresenius Kabi
close

Seizing opportunities > for better health

At Fresenius Helios, our commitment is to provide the highest medical quality and care. We aim to offer advanced and proven best-in-class diagnosis and treatment methods for the benefit of our patients. We continuously invest in high-quality, state-of-the-art medicine, and aim to measure and improve the quality of medical care.

Our target ist that our quality indicators should be better than the German average. With a mortality rate of SMR < 1, this was accomplished, among others, for major illnesses shown below.

HELIOS QUALITY INDICATORS
Indications/
standardized mortality rate (SMR)*
2008
SMR
2007
SMR
Acute myocardial infarction 0.73 0.79
Heart failure 0.73 0.85
Stroke 0.83 1.01
Acute cerebral infarction 0.81 0.99
Pneumonia 0.71 0.85
 

READ MORE ABOUT FRESENIUS HELIOS >> 

close
for better health - Fresenius Helios
close

Seizing opportunities > for greater efficiency

Fresenius Vamed is a leading international provider of services in the planning, construction, and management of health care facilities. Our complete value chain and our more than 25 years of international experience are key to providing effective support for hospitals at every stage of their life cycle, and thus contributing towards their successful operating performance. For us, each project is another opportunity to prove our competence.

Hospitals face the dual challenge of increasing efficiency and reducing expenditure. We support hospitals by offering comprehensive process know-how and by taking over medical-technical services and management functions.

VAMED SERVICES
   
Service contracts* for   140 clinics
  ~ 50,000 beds
among others:  
Vienna General Hospital and University Clinics (AKH) ~ 2,100 beds
Charité Hospital Berlin ~ 3,200 beds
University Clinic Hamburg-Eppendorf ~1,370 beds
Prince Court Medical Center, Kuala Lumpur ~ 330 beds
Al Ain Hospital, Abu Dhabi ~ 450 beds
 

READ MORE ABOUT FRESENIUS VAMED >>

close
for greater efficiency - Fresenius Vamed
  • Print page
  • Save as PDF
  • Add to Cart
  • Recommend Page
Home arrow Fresenius Group arrow Fresenius Shares

Print

INVESTOR RELATIONS

Our Investor Relations activities are in accordance with the transparency rules of the German Corporate Governance Code. We pursue comprehensive, timely, and open communication with private and institutional investors as well as financial analysts. The equal treatment of all market actors is very important to us in our day-to-day communication.

In 2008, we again intensified our dialogue with the capital market in order to enable investors and analysts to make a fair assessment of Fresenius Group’s business situation and market conditions. In addition to the annual analysts’ meeting and the quarterly conference calls, Fresenius also made presentations in important financial markets in Europe and the United States. Regular contacts were further extended at ten international investor conferences, 17 roadshows, and numerous one-on-one meetings with institutional investors and analysts. A Capital Market Day was also held in December 2008 at which the managements teams of Fresenius Helios and Fresenius Vamed informed analysts and investors in detail about the business, strategies, and growth prospects.

We also used the Internet to intensify the dialogue with our private investors. Our private shareholders can follow live webcasts of the quarterly conference calls and annual analysts’ meeting on our website at www.fresenius.com.  Presentations can be downloaded shortly before and, of course, after the events in the Investor Relations section under “Presentations.” We also publish all presentations by the Management Board given at international investor conferences. We intend to make further improvements in the ways we communicate with private shareholders, and would welcome any suggestions you may care to make. In 2009, we also plan to increase the information content of our website.

In 2008, we again received important commendations for the standard of our financial communications. In the competition for the best annual report conducted by the German business magazine manager magazin, which analyzed more than 200 annual reports published by German and European companies, we came fourth in the MDAX category and tenth in the overall ranking. In addition, we again received the Platinum Award for our annual report in the category “Health Care – Equipment&Supplies” from the League of American Communications Professionals (LACP). In the overall rating for all categories, Fresenius ranked a very good 21st, an improvement of four places over the previous year. Over 3,100 companies from 21 countries took part in this contest. Fresenius SE’s online annual report won a prize at the ARC Awards in the Honor Award category. The independent US organization Mercomm, Inc. has been making internationally renowned awards for annual reports published by listed and private companies since 1987. In 2008, the jury reviewed a total of 2,100 annual reports from 28 countries, including 98 online reports. The jury was particularly impressed by the low-key design used to convey our healthcare group’s image, the easy-to-read pages with a balanced mix of text and images, and the explanation of technical terms included directly in the text. In a study by the company NetFederation, Fresenius SE’s Investor Relations website was ranked 6th under 110 websites of companies, listed in a Deutsche Börse index. Major criteria were story, service, technology and design. The annual study shows the quality of online Investor Relations of German companies.

Fresenius SE was awarded “Deal of the Year Award 2008” in the category Corporate Finance for its July issue of a Mandatory Excheangable Bond, to partially finance the acquisition of APP Pharmaceuticals. It was the last major equity-linked transaction in the market in 2008 and the only mandatory security in Europe during the year. The award was awarded by the Association of Corporate Treasurers (ACT), London.